Приказ основних података о документу
Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients
dc.creator | Mijevic, Cedo | |
dc.creator | Nikolić, Milan | |
dc.creator | Nikolić-Kokić, Aleksandra | |
dc.creator | Jones, David R. | |
dc.creator | Niketić, Vesna | |
dc.creator | Lecic-Tosevski, Dusica | |
dc.creator | Spasić, Mihajlo B. | |
dc.date.accessioned | 2018-11-22T00:16:07Z | |
dc.date.available | 2018-11-22T00:16:07Z | |
dc.date.issued | 2010 | |
dc.identifier.issn | 0278-5846 | |
dc.identifier.uri | https://cherry.chem.bg.ac.rs/handle/123456789/1059 | |
dc.description.abstract | Objective: Despite clozapine's unique effectiveness in patients with schizophrenia, a number of adverse effects have been recognised including abnormalities in lipid and glucose metabolisms. A high clozapine level in red blood cells (RBCs) and disturbed anti-oxidant enzyme activities in blood from schizophrenic patients prompted us to investigate lipid status and anti-oxidant enzyme defence in the blood of chronic schizophrenic patients on long-term clozapine therapy. Methods: Plasma lipids, RBC anti-oxidant enzyme activities and haemoglobin (Hb) content were measured using established procedures in a group of eighteen chronically-medicated (average 630 days of therapy) schizophrenic patients receiving clozapine (average dose of 295 mg/day) and data were compared with those from a group of eighteen well-matched normal controls. Results: Significantly higher levels of plasma triglycerides (by 47%, p lt 0.01) and total cholesterol and phospholipids (by 8% and 11%, respectively p lt 0.05) in patients were found. CuZn-superoxide dismutase (SOD1) activity was markedly higher (by 35%, p lt 0.001) while selenium-dependent glutathione peroxidase (GSH-Px1) activity was markedly lower (by 41%, p lt 0.001) in patients. In addition, metHb and HbA1c levels in patients were significantly higher (by 58% and 25%. respectively p lt 0.001). SOD1 activity was negatively correlated (p lt 0.001) to GSH-Px1 activity in patients. Conclusions:The findings support the view that ongoing oxidative stress may be a mechanism by which clozapine induces some adverse effects that increase the risk of diabetes and metabolic syndrome. If valid, this would indicate that in parallel with long-term clozapine treatment, schizophrenic patients could be encouraged to make some lifestyle changes to limit the detrimental effects of the medication. (C) 2009 Elsevier Inc. All rights reserved. | en |
dc.publisher | Pergamon-Elsevier Science Ltd, Oxford | |
dc.relation | info:eu-repo/grantAgreement/MESTD/MPN2006-2010/142017/RS// | |
dc.relation | info:eu-repo/grantAgreement/MESTD/MPN2006-2010/143034/RS// | |
dc.rights | restrictedAccess | |
dc.source | Progress in Neuro-psychopharmacology and Biological Psychiatry | |
dc.subject | Anti-oxidant enzymes | en |
dc.subject | Clozapine | en |
dc.subject | Oxidative stress | en |
dc.subject | Red blood cells | en |
dc.subject | Schizophrenia | en |
dc.title | Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Никетиц, Весна; Јонес, Давид Р.; Николиц-Кокиц, Aлександра; Мијевиц, Цедо; Спасиц, Михајло Б.; Николић, Милан; Лециц-Тосевски, Дусица; | |
dc.citation.volume | 34 | |
dc.citation.issue | 2 | |
dc.citation.spage | 303 | |
dc.citation.epage | 307 | |
dc.identifier.wos | 000275790500008 | |
dc.identifier.doi | 10.1016/j.pnpbp.2009.11.024 | |
dc.citation.other | 34(2): 303-307 | |
dc.citation.rank | M21 | |
dc.identifier.pmid | 19962416 | |
dc.type.version | publishedVersion | en |
dc.identifier.scopus | 2-s2.0-77649274503 |